Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy MEI Pharma stock
Learn how to easily invest in MEI Pharma stock.
MEI Pharma Inc is a biotechnology business based in the US. MEI Pharma shares (MEIP) are listed on the NASDAQ and all prices are listed in US Dollars. MEI Pharma employs 102 staff and has a trailing 12-month revenue of around $40.7 million.
How to buy shares in MEI Pharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MEIP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
MEI Pharma stock price (NASDAQ: MEIP)Use our graph to track the performance of MEIP stocks over time.
MEI Pharma shares at a glance
|Latest market close||$0.40|
|52-week range||$0.41 - $3.55|
|50-day moving average||$0.51|
|200-day moving average||$1.15|
|Wall St. target price||$5.17|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.52|
Buy MEI Pharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy MEI Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MEI Pharma price performance over time
|1 week (2022-09-20)||-9.09%|
|1 month (2022-08-26)||-24.53%|
|3 months (2022-06-27)||-38.46%|
|6 months (2022-03-23)||N/A|
|1 year (2021-09-27)||-86.35%|
|2 years (2020-09-25)||-87.18%|
|3 years (2019-09-27)||1.7|
|5 years (2017-09-27)||2.73|
Is MEI Pharma stock undervalued or overvalued?
Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MEI Pharma's PEG ratio
MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
MEI Pharma financials
|Revenue TTM||$40.7 million|
|Gross profit TTM||$40.7 million|
|Return on assets TTM||-26.81%|
|Return on equity TTM||-106.9%|
|Market capitalisation||$55.3 million|
TTM: trailing 12 months
MEI Pharma share dividends
We're not expecting MEI Pharma to pay a dividend over the next 12 months.
Have MEI Pharma's shares ever split?
MEI Pharma's shares were split on a 1:6 basis on 18 December 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.
MEI Pharma share price volatility
Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $0.41 up to $3.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 0.809. This would suggest that MEI Pharma's shares are less volatile than average (for this exchange).
MEI Pharma overview
MEI Pharma, Inc. , a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd. ; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.
MEI Pharma in the news
MEI Pharma Announces Changes to Board of Directors
Edited Transcript of MEIP.OQ earnings conference call or presentation 8-Sep-22 9:00pm GMT
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
Frequently asked questionsWhat percentage of MEI Pharma is owned by insiders or institutions?
Currently 0.491% of MEI Pharma shares are held by insiders and 38.002% by institutions. How many people work for MEI Pharma?
Latest data suggests 102 work at MEI Pharma. When does the fiscal year end for MEI Pharma?
MEI Pharma's fiscal year ends in June. Where is MEI Pharma based?
MEI Pharma's address is: 11455 El Camino Real, San Diego, CA, United States, 92130 What is MEI Pharma's ISIN number?
MEI Pharma's international securities identification number is: US55279B2025 What is MEI Pharma's CUSIP number?
MEI Pharma's Committee on Uniform Securities Identification Procedures number is: 55279B103
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert